Beth Israel Medical Center

Mount Sinai Health System opens the Hamilton and Amabel James Center for AI and Human Health, a 12-story, 65,000-square-foot facility dedicated to enhancing healthcare through AI research and development, supported by a generous gift from Hamilton and Amabel James.

FDA approves Bimzelx, developed by UCB, for moderate-to-severe hidradenitis suppurativa (HS), targeting IL-17F and IL-17A. Clinical studies showed deep and sustained responses up to 48 weeks, addressing significant unmet needs. Bimzelx is now available for HS patients in the U.S., marking a significant step in treating chronic inflammatory diseases.